{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:51:46Z","timestamp":1792785106683,"version":"4.5.0"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:00:00Z","timestamp":1792108800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:00:00Z","timestamp":1792108800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"FAILSAFE Funding: Accelerating Global Solutions to Antifungal Resistance"},{"name":"US National Institute of Allergy and Infectious Diseases","award":["AI187391"],"award-info":[{"award-number":["AI187391"]}],"id":[{"id":"https:\/\/ror.org\/043z4tv69","id-type":"ROR","asserted-by":"crossref"}]},{"name":"US National Institute of Allergy and Infectious Diseases","award":["AI187391"],"award-info":[{"award-number":["AI187391"]}],"id":[{"id":"https:\/\/ror.org\/043z4tv69","id-type":"ROR","asserted-by":"crossref"}]},{"name":"US National Institute of Allergy and Infectious Diseases","award":["AI187391"],"award-info":[{"award-number":["AI187391"]}],"id":[{"id":"https:\/\/ror.org\/043z4tv69","id-type":"ROR","asserted-by":"crossref"}]},{"name":"UF Center for Translational Research in Neurodegenerative Disease Bridge Funding"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Fungal Sci."],"DOI":"10.1038\/s44512-026-00007-y","type":"journal-article","created":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T12:57:51Z","timestamp":1792155471000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Iturin A disrupts Cryptococcus neoformans membrane integrity, attenuates virulence, and synergizes with amphotericin B"],"prefix":"10.1038","volume":"1","author":[{"given":"Yehia","family":"Elgammal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael I. Garcia","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia L.","family":"Charles-Ni\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6372-6501","authenticated-orcid":false,"given":"Luis R.","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,16]]},"reference":[{"key":"7_CR1","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s12934-024-02369-2","volume":"23","author":"W Qian","year":"2024","unstructured":"Qian, W. et al. Deciphering antifungal and antibiofilm mechanisms of isobavachalcone against Cryptococcus neoformans through RNA-seq and functional analyses. Microb. Cell Fact. 23, 107, https:\/\/doi.org\/10.1186\/s12934-024-02369-2 (2024).","journal-title":"Microb. Cell Fact."},{"key":"7_CR2","doi-asserted-by":"publisher","first-page":"i2","DOI":"10.1093\/jac\/dkaf004","volume":"80","author":"L Pagano","year":"2025","unstructured":"Pagano, L. & Fernandez, O. M. Clinical aspects and recent advances in fungal diseases impacting human health. J. Antimicrob. Chemother. 80, i2\u2013i8, https:\/\/doi.org\/10.1093\/jac\/dkaf004 (2025).","journal-title":"J. Antimicrob. Chemother."},{"key":"7_CR3","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1164\/rccm.202410-2076OC","volume":"211","author":"Y Xia","year":"2025","unstructured":"Xia, Y. et al. Global, regional, and national burden of pulmonary fungal infections 1990\u20132021. Am. J. Respir. Crit. Care Med. 211, 1007\u20131017, https:\/\/doi.org\/10.1164\/rccm.202410-2076OC (2025).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"7_CR4","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1021\/acsinfecdis.4c00975","volume":"11","author":"D Desmarini","year":"2025","unstructured":"Desmarini, D. et al. Synthesis of a new purine analogue class with antifungal activity and improved potency against fungal IP(3-4)K. ACS Infect. Dis. 11, 940\u2013953, https:\/\/doi.org\/10.1021\/acsinfecdis.4c00975 (2025).","journal-title":"ACS Infect. Dis."},{"key":"7_CR5","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1128\/iai.17.3.634-638.1977","volume":"17","author":"JB Neilson","year":"1977","unstructured":"Neilson, J. B., Fromtling, R. A. & Bulmer, G. S. Cryptococcus neoformans: size range of infectious particles from aerosolized soil. Infect. Immun. 17, 634\u2013638, https:\/\/doi.org\/10.1128\/iai.17.3.634-638.1977 (1977).","journal-title":"Infect. Immun."},{"key":"7_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1174967","volume":"14","author":"J Chen","year":"2023","unstructured":"Chen, J., Shao, J., Dai, M., Fang, W. & Yang, Y. L. Adaptive immunology of Cryptococcus neoformans infections\u2014an update. Front Immunol. 14, 1174967. https:\/\/doi.org\/10.3389\/fimmu.2023.1174967 (2023).","journal-title":"Front Immunol."},{"key":"7_CR7","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1034\/j.1600-6143.2002.20701.x","volume":"2","author":"RA Vilchez","year":"2002","unstructured":"Vilchez, R. A., Fung, J. & Kusne, S. Cryptococcosis in organ transplant recipients: an overview. Am. J. Transpl. 2, 575\u2013580, https:\/\/doi.org\/10.1034\/j.1600-6143.2002.20701.x (2002).","journal-title":"Am. J. Transpl."},{"key":"7_CR8","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1086\/649861","volume":"50","author":"JC Nussbaum","year":"2010","unstructured":"Nussbaum, J. C. et al. Combination flucytosine and high-dose fluconazole compared with fluconazole monotherapy for the treatment of cryptococcal meningitis: a randomized trial in Malawi. Clin. Infect. Dis. 50, 338\u2013344, https:\/\/doi.org\/10.1086\/649861 (2010).","journal-title":"Clin. Infect. Dis."},{"key":"7_CR9","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1016\/S1473-3099(22)00499-6","volume":"22","author":"R Rajasingham","year":"2022","unstructured":"Rajasingham, R. et al. The global burden of HIV-associated cryptococcal infection in adults in 2020: a modelling analysis. Lancet Infect. Dis. 22, 1748\u20131755, https:\/\/doi.org\/10.1016\/S1473-3099(22)00499-6 (2022).","journal-title":"Lancet Infect. Dis."},{"key":"7_CR10","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1007\/s40588-016-0035-5","volume":"3","author":"MW Tenforde","year":"2016","unstructured":"Tenforde, M. W., Wake, R., Leeme, T. & Jarvis, J. N. HIV-associated cryptococcal meningitis: bridging the gap between developed and resource-limited settings. Curr. Clin. Microbiol. Rep. 3, 92\u2013102, https:\/\/doi.org\/10.1007\/s40588-016-0035-5 (2016).","journal-title":"Curr. Clin. Microbiol. Rep."},{"key":"7_CR11","doi-asserted-by":"publisher","unstructured":"Denham, S. T. et al. Regulated release of cryptococcal polysaccharide drives virulence and suppresses immune cell infiltration into the central nervous system. Infect. Immun. 86, https:\/\/doi.org\/10.1128\/IAI.00662-17 (2018).","DOI":"10.1128\/IAI.00662-17"},{"key":"7_CR12","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1080\/mmy.38.6.407.417","volume":"38","author":"A Vecchiarelli","year":"2000","unstructured":"Vecchiarelli, A. Immunoregulation by capsular components of Cryptococcus neoformans. Med. Mycol. 38, 407\u2013417, https:\/\/doi.org\/10.1080\/mmy.38.6.407.417 (2000).","journal-title":"Med. Mycol."},{"key":"7_CR13","doi-asserted-by":"publisher","first-page":"6350","DOI":"10.1128\/IAI.73.10.6350-6362.2005","volume":"73","author":"LR Martinez","year":"2005","unstructured":"Martinez, L. R. & Casadevall, A. Specific antibody can prevent fungal biofilm formation and this effect correlates with protective efficacy. Infect. Immun. 73, 6350\u20136362, https:\/\/doi.org\/10.1128\/IAI.73.10.6350-6362.2005 (2005).","journal-title":"Infect. Immun."},{"key":"7_CR14","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/S0065-2164(09)01204-0","volume":"68","author":"O Zaragoza","year":"2009","unstructured":"Zaragoza, O. et al. The capsule of the fungal pathogen Cryptococcus neoformans. Adv. Appl. Microbiol. 68, 133\u2013216, https:\/\/doi.org\/10.1016\/S0065-2164(09)01204-0 (2009).","journal-title":"Adv. Appl. Microbiol."},{"key":"7_CR15","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1128\/AAC.50.3.1021-1033.2006","volume":"50","author":"LR Martinez","year":"2006","unstructured":"Martinez, L. R. & Casadevall, A. Susceptibility of Cryptococcus neoformans biofilms to antifungal agents in vitro. Antimicrob. Agents Chemother. 50, 1021\u20131033, https:\/\/doi.org\/10.1128\/AAC.50.3.1021-1033.2006 (2006).","journal-title":"Antimicrob. Agents Chemother."},{"key":"7_CR16","doi-asserted-by":"publisher","first-page":"6118","DOI":"10.1128\/IAI.00995-06","volume":"74","author":"LR Martinez","year":"2006","unstructured":"Martinez, L. R. & Casadevall, A. Cryptococcus neoformans cells in biofilms are less susceptible than planktonic cells to antimicrobial molecules produced by the innate immune system. Infect. Immun. 74, 6118\u20136123, https:\/\/doi.org\/10.1128\/IAI.00995-06 (2006).","journal-title":"Infect. Immun."},{"key":"7_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1681033","volume":"16","author":"ME Munzen","year":"2025","unstructured":"Munzen, M. E. et al. Cryptococcus neoformans phospholipase B1 is critical for cryptococcoma formation in the mouse brain. Front. Immunol. 16, 1681033. https:\/\/doi.org\/10.3389\/fimmu.2025.1681033 (2025).","journal-title":"Front. Immunol."},{"key":"7_CR18","doi-asserted-by":"publisher","unstructured":"Aslanyan, L. et al. The crucial role of biofilms in Cryptococcus neoformans survival within macrophages and colonization of the central nervous system. J. Fungi (Basel) 3, https:\/\/doi.org\/10.3390\/jof3010010 (2017).","DOI":"10.3390\/jof3010010"},{"key":"7_CR19","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1227\/00006123-198603000-00025","volume":"18","author":"TJ Walsh","year":"1986","unstructured":"Walsh, T. J., Schlegel, R., Moody, M. M., Costerton, J. W. & Salcman, M. Ventriculoatrial shunt infection due to Cryptococcus neoformans: an ultrastructural and quantitative microbiological study. Neurosurgery 18, 373\u2013375, https:\/\/doi.org\/10.1227\/00006123-198603000-00025 (1986).","journal-title":"Neurosurgery"},{"key":"7_CR20","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1038\/s41579-021-00511-0","volume":"19","author":"KR Iyer","year":"2021","unstructured":"Iyer, K. R., Revie, N. M., Fu, C., Robbins, N. & Cowen, L. E. Treatment strategies for cryptococcal infection: challenges, advances and future outlook. Nat. Rev. Microbiol. 19, 454\u2013466, https:\/\/doi.org\/10.1038\/s41579-021-00511-0 (2021).","journal-title":"Nat. Rev. Microbiol."},{"key":"7_CR21","unstructured":"World Health Organization. Guidelines for diagnosing, preventing and managing cryptococcal disease among adults, adolescents and children living with HIV. (2022)."},{"key":"7_CR22","doi-asserted-by":"publisher","unstructured":"Milsap, D. et al. Induction treatment for HIV-associated cryptococcal meningitis: where have we been and where are we going? Microorganisms 13, https:\/\/doi.org\/10.3390\/microorganisms13040847 (2025).","DOI":"10.3390\/microorganisms13040847"},{"key":"7_CR23","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1056\/NEJM199203193261203","volume":"326","author":"WG Powderly","year":"1992","unstructured":"Powderly, W. G. et al.The NIAID AIDS Clinical Trials Group and Mycoses Study Group A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome. N. Engl. J. Med. 326, 793\u2013798, https:\/\/doi.org\/10.1056\/NEJM199203193261203 (1992).","journal-title":"N. Engl. J. Med."},{"key":"7_CR24","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.2217\/fmb-2022-0269","volume":"18","author":"ME Munzen","year":"2023","unstructured":"Munzen, M. E., Goncalves Garcia, A. D. & Martinez, L. R. An update on the global treatment of invasive fungal infections. Future Microbiol. 18, 1095\u20131117, https:\/\/doi.org\/10.2217\/fmb-2022-0269 (2023).","journal-title":"Future Microbiol."},{"key":"7_CR25","doi-asserted-by":"publisher","unstructured":"Yaraguppi, D. A., Bagewadi, Z. K., Patil, N. R. & Mantri, N. Iturin: a promising cyclic lipopeptide with diverse applications. Biomolecules 13, https:\/\/doi.org\/10.3390\/biom13101515 (2023).","DOI":"10.3390\/biom13101515"},{"key":"7_CR26","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1111\/j.1574-6968.1995.tb07507.x","volume":"128","author":"L Thimon","year":"1995","unstructured":"Thimon, L., Peypoux, F., Wallach, J. & Michel, G. Effect of the lipopeptide antibiotic, iturin A, on morphology and membrane ultrastructure of yeast cells. FEMS Microbiol. Lett. 128, 101\u2013106, https:\/\/doi.org\/10.1111\/j.1574-6968.1995.tb07507.x (1995).","journal-title":"FEMS Microbiol. Lett."},{"key":"7_CR27","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/BF00436368","volume":"116","author":"MA Klich","year":"1991","unstructured":"Klich, M. A., Lax, A. R. & Bland, J. M. Inhibition of some mycotoxigenic fungi by iturin A, a peptidolipid produced by Bacillus subtilis. Mycopathologia 116, 77\u201380, https:\/\/doi.org\/10.1007\/BF00436368 (1991).","journal-title":"Mycopathologia"},{"key":"7_CR28","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1176\/ajp.143.12.aj143121628","volume":"143","author":"GE Gorton","year":"1986","unstructured":"Gorton, G. E. On alexithymic expression and behavior. Am. J. Psychiatry 143, 1628\u20131629, https:\/\/doi.org\/10.1176\/ajp.143.12.aj143121628 (1986).","journal-title":"Am. J. Psychiatry"},{"key":"7_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2024.134306","volume":"277","author":"S Yang","year":"2024","unstructured":"Yang, S. et al. Insights into the antifungal mechanism of Bacillus subtilis cyclic lipopeptide iturin A mediated by potassium ion channel. Int. J. Biol. Macromol. 277, 134306. https:\/\/doi.org\/10.1016\/j.ijbiomac.2024.134306 (2024).","journal-title":"Int. J. Biol. Macromol."},{"key":"7_CR30","doi-asserted-by":"publisher","first-page":"4377","DOI":"10.1007\/s00253-019-09805-z","volume":"103","author":"S Lei","year":"2019","unstructured":"Lei, S. et al. Capability of iturin from Bacillus subtilis to inhibit Candida albicans in vitro and in vivo. Appl. Microbiol. Biotechnol. 103, 4377\u20134392, https:\/\/doi.org\/10.1007\/s00253-019-09805-z (2019).","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"7_CR31","doi-asserted-by":"publisher","first-page":"3759","DOI":"10.1007\/s00253-021-11296-w","volume":"105","author":"L Zhou","year":"2021","unstructured":"Zhou, L. et al. Antifungal activity of silver nanoparticles synthesized by iturin against Candida albicans in vitro and in vivo. Appl. Microbiol. Biotechnol. 105, 3759\u20133770, https:\/\/doi.org\/10.1007\/s00253-021-11296-w (2021).","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"7_CR32","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00948-23","volume":"68","author":"D Han","year":"2024","unstructured":"Han, D. et al. Therapeutic effect of iturin A on Candida albicans oral infection and its pathogenic factors. Antimicrob. Agents Chemother. 68, e0094823. https:\/\/doi.org\/10.1128\/aac.00948-23 (2024).","journal-title":"Antimicrob. Agents Chemother."},{"key":"7_CR33","doi-asserted-by":"publisher","first-page":"286","DOI":"10.3389\/fmicb.2012.00286","volume":"3","author":"AC Mesa-Arango","year":"2012","unstructured":"Mesa-Arango, A. C., Scorzoni, L. & Zaragoza, O. It only takes one to do many jobs: amphotericin B as antifungal and immunomodulatory drug. Front. Microbiol. 3, 286, https:\/\/doi.org\/10.3389\/fmicb.2012.00286 (2012).","journal-title":"Front. Microbiol."},{"key":"7_CR34","doi-asserted-by":"publisher","first-page":"6155","DOI":"10.1128\/IAI.71.11.6155-6164.2003","volume":"71","author":"O Zaragoza","year":"2003","unstructured":"Zaragoza, O., Fries, B. C. & Casadevall, A. Induction of capsule growth in Cryptococcus neoformans by mammalian serum and CO(2). Infect. Immun. 71, 6155\u20136164, https:\/\/doi.org\/10.1128\/IAI.71.11.6155-6164.2003 (2003).","journal-title":"Infect. Immun."},{"key":"7_CR35","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1093\/infdis\/jit435","volume":"209","author":"EJ Robertson","year":"2014","unstructured":"Robertson, E. J. et al. Cryptococcus neoformans ex vivo capsule size is associated with intracranial pressure and host immune response in HIV-associated cryptococcal meningitis. J. Infect. Dis. 209, 74\u201382, https:\/\/doi.org\/10.1093\/infdis\/jit435 (2014).","journal-title":"J. Infect. Dis."},{"key":"7_CR36","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1111\/j.1462-5822.2008.01186.x","volume":"10","author":"O Zaragoza","year":"2008","unstructured":"Zaragoza, O. et al. Capsule enlargement in Cryptococcus neoformans confers resistance to oxidative stress suggesting a mechanism for intracellular survival. Cell. Microbiol. 10, 2043\u20132057, https:\/\/doi.org\/10.1111\/j.1462-5822.2008.01186.x (2008).","journal-title":"Cell. Microbiol."},{"key":"7_CR37","doi-asserted-by":"publisher","first-page":"3165","DOI":"10.1073\/pnas.052702799","volume":"99","author":"SC Tucker","year":"2002","unstructured":"Tucker, S. C. & Casadevall, A. Replication of Cryptococcus neoformans in macrophages is accompanied by phagosomal permeabilization and accumulation of vesicles containing polysaccharide in the cytoplasm. Proc. Natl. Acad. Sci. USA 99, 3165\u20133170, https:\/\/doi.org\/10.1073\/pnas.052702799 (2002).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"7_CR38","doi-asserted-by":"publisher","first-page":"e1007144","DOI":"10.1371\/journal.ppat.1007144","volume":"14","author":"MS Fu","year":"2018","unstructured":"Fu, M. S. et al. Cryptococcus neoformans urease affects the outcome of intracellular pathogenesis by modulating phagolysosomal pH. PLoS Pathog. 14, e1007144, https:\/\/doi.org\/10.1371\/journal.ppat.1007144 (2018).","journal-title":"PLoS Pathog."},{"key":"7_CR39","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1371\/journal.ppat.0030018","volume":"3","author":"J Breger","year":"2007","unstructured":"Breger, J. et al. Antifungal chemical compounds identified using a C. elegans pathogenicity assay. PLoS Pathog. 3, e18, https:\/\/doi.org\/10.1371\/journal.ppat.0030018 (2007).","journal-title":"PLoS Pathog."},{"key":"7_CR40","doi-asserted-by":"publisher","unstructured":"Martinez, M., Cruz, M. R., Garsin, D. A. & Lorenz, M. C. C. elegans as a tractable infection model for the emerging fungal pathogen Candida auris. Microbiol. Spectr. e0315625, https:\/\/doi.org\/10.1128\/spectrum.03156-25 (2026).","DOI":"10.1128\/spectrum.03156-25"},{"key":"7_CR41","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1002\/9780470559277.ch130160","volume":"6","author":"AL Conery","year":"2014","unstructured":"Conery, A. L., Larkins-Ford, J., Ausubel, F. M. & Kirienko, N. V. High-throughput screening for novel anti-infectives using a C. elegans pathogenesis model. Curr. Protoc. Chem. Biol. 6, 25\u201337, https:\/\/doi.org\/10.1002\/9780470559277.ch130160 (2014).","journal-title":"Curr. Protoc. Chem. Biol."},{"key":"7_CR42","doi-asserted-by":"publisher","first-page":"10892","DOI":"10.1073\/pnas.191378698","volume":"98","author":"DA Garsin","year":"2001","unstructured":"Garsin, D. A. et al. A simple model host for identifying Gram-positive virulence factors. Proc. Natl. Acad. Sci. USA 98, 10892\u201310897, https:\/\/doi.org\/10.1073\/pnas.191378698 (2001).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"7_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcrc.2010.08.005","volume":"26","author":"M Klepser","year":"2011","unstructured":"Klepser, M. The value of amphotericin B in the treatment of invasive fungal infections. J. Crit. Care 26, 225 e221-210. https:\/\/doi.org\/10.1016\/j.jcrc.2010.08.005 (2011).","journal-title":"J. Crit. Care"},{"key":"7_CR44","doi-asserted-by":"publisher","first-page":"805","DOI":"10.4065\/mcp.2011.0247","volume":"86","author":"RE Lewis","year":"2011","unstructured":"Lewis, R. E. Current concepts in antifungal pharmacology. Mayo Clin. Proc. 86, 805\u2013817, https:\/\/doi.org\/10.4065\/mcp.2011.0247 (2011).","journal-title":"Mayo Clin. Proc."},{"key":"7_CR45","doi-asserted-by":"publisher","unstructured":"Aaron, P. A., Vu, K. & Gelli, A. An antivirulence approach for preventing Cryptococcus neoformans from crossing the blood\u2013brain barrier via novel natural product inhibitors of a fungal metalloprotease. mBio 11, https:\/\/doi.org\/10.1128\/mBio.01249-20 (2020).","DOI":"10.1128\/mBio.01249-20"},{"key":"7_CR46","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s15010-018-1152-2","volume":"46","author":"K Goralska","year":"2018","unstructured":"Goralska, K., Blaszkowska, J. & Dzikowiec, M. Neuroinfections caused by fungi. Infection 46, 443\u2013459, https:\/\/doi.org\/10.1007\/s15010-018-1152-2 (2018).","journal-title":"Infection"},{"key":"7_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-43941-w","volume":"9","author":"JC Hurtado","year":"2019","unstructured":"Hurtado, J. C. et al. Mortality due to Cryptococcus neoformans and Cryptococcus gattii in low-income settings: an autopsy study. Sci. Rep. 9, 7493. https:\/\/doi.org\/10.1038\/s41598-019-43941-w (2019).","journal-title":"Sci. Rep."},{"key":"7_CR48","doi-asserted-by":"publisher","unstructured":"Ahmed, M. U. et al. Potential toxicity of polymyxins in human lung epithelial cells. Antimicrob. Agents Chemother. 61, https:\/\/doi.org\/10.1128\/AAC.02690-16 (2017).","DOI":"10.1128\/AAC.02690-16"},{"key":"7_CR49","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1006\/excr.1998.4172","volume":"243","author":"KA Foster","year":"1998","unstructured":"Foster, K. A., Oster, C. G., Mayer, M. M., Avery, M. L. & Audus, K. L. Characterization of the A549 cell line as a type II pulmonary epithelial cell model for drug metabolism. Exp. Cell Res. 243, 359\u2013366, https:\/\/doi.org\/10.1006\/excr.1998.4172 (1998).","journal-title":"Exp. Cell Res."},{"key":"7_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijfoodmicro.2020.108783","volume":"330","author":"C Jiang","year":"2020","unstructured":"Jiang, C. et al. Bacillus subtilis inhibits Aspergillus carbonarius by producing iturin A, which disturbs the transport, energy metabolism, and osmotic pressure of fungal cells as revealed by transcriptomics analysis. Int. J. Food Microbiol. 330, 108783. https:\/\/doi.org\/10.1016\/j.ijfoodmicro.2020.108783 (2020).","journal-title":"Int. J. Food Microbiol."},{"key":"7_CR51","doi-asserted-by":"publisher","unstructured":"Singh, P. et al. A Thermotolerant marine Bacillus amyloliquefaciens S185 producing Iturin A5 for antifungal activity against Fusarium oxysporum f. sp. cubense. Mar. Drugs 19, https:\/\/doi.org\/10.3390\/md19090516 (2021).","DOI":"10.3390\/md19090516"},{"key":"7_CR52","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.bbamem.2005.05.003","volume":"1713","author":"FJ Aranda","year":"2005","unstructured":"Aranda, F. J., Teruel, J. A. & Ortiz, A. Further aspects on the hemolytic activity of the antibiotic lipopeptide iturin A. Biochim. Biophys. Acta 1713, 51\u201356, https:\/\/doi.org\/10.1016\/j.bbamem.2005.05.003 (2005).","journal-title":"Biochim. Biophys. Acta"},{"key":"7_CR53","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/0300-483x(94)90159-7","volume":"87","author":"R Maget-Dana","year":"1994","unstructured":"Maget-Dana, R. & Peypoux, F. Iturins, a special class of pore-forming lipopeptides: biological and physicochemical properties. Toxicology 87, 151\u2013174, https:\/\/doi.org\/10.1016\/0300-483x(94)90159-7 (1994).","journal-title":"Toxicology"},{"key":"7_CR54","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1016\/j.bbamem.2012.01.020","volume":"1818","author":"MN Nasir","year":"2012","unstructured":"Nasir, M. N. & Besson, F. Interactions of the antifungal mycosubtilin with ergosterol-containing interfacial monolayers. Biochim. Biophys. Acta 1818, 1302\u20131308, https:\/\/doi.org\/10.1016\/j.bbamem.2012.01.020 (2012).","journal-title":"Biochim. Biophys. Acta"},{"key":"7_CR55","doi-asserted-by":"publisher","first-page":"138","DOI":"10.4014\/jmb.0905.05007","volume":"20","author":"PI Kim","year":"2010","unstructured":"Kim, P. I., Ryu, J., Kim, Y. H. & Chi, Y. T. Production of biosurfactant lipopeptides Iturin A, fengycin and surfactin A from Bacillus subtilis CMB32 for control of Colletotrichum gloeosporioides. J. Microbiol Biotechnol. 20, 138\u2013145 (2010).","journal-title":"J. Microbiol Biotechnol."},{"key":"7_CR56","doi-asserted-by":"publisher","first-page":"6414","DOI":"10.1002\/jcp.27377","volume":"234","author":"H Zhao","year":"2019","unstructured":"Zhao, H. et al. Iturin A-like lipopeptides from Bacillus subtilis trigger apoptosis, paraptosis, and autophagy in Caco-2 cells. J. Cell Physiol. 234, 6414\u20136427, https:\/\/doi.org\/10.1002\/jcp.27377 (2019).","journal-title":"J. Cell Physiol."},{"key":"7_CR57","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1128\/IAI.01065-08","volume":"77","author":"C Charlier","year":"2009","unstructured":"Charlier, C. et al. Evidence of a role for monocytes in dissemination and brain invasion by Cryptococcus neoformans. Infect. Immun. 77, 120\u2013127, https:\/\/doi.org\/10.1128\/IAI.01065-08 (2009).","journal-title":"Infect. Immun."},{"key":"7_CR58","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.micinf.2015.08.017","volume":"18","author":"TC Sorrell","year":"2016","unstructured":"Sorrell, T. C. et al. Cryptococcal transmigration across a model brain blood-barrier: evidence of the Trojan horse mechanism and differences between Cryptococcus neoformans var. grubii strain H99 and Cryptococcus gattii strain R265. Microbes Infect. 18, 57\u201367, https:\/\/doi.org\/10.1016\/j.micinf.2015.08.017 (2016).","journal-title":"Microbes Infect."},{"key":"7_CR59","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.4049\/jimmunol.1402376","volume":"194","author":"MJ Davis","year":"2015","unstructured":"Davis, M. J. et al. Cryptococcus neoformans-induced macrophage lysosome damage crucially contributes to fungal virulence. J. Immunol. 194, 2219\u20132231, https:\/\/doi.org\/10.4049\/jimmunol.1402376 (2015).","journal-title":"J. Immunol."},{"key":"7_CR60","doi-asserted-by":"publisher","first-page":"3450","DOI":"10.1128\/IAI.00297-09","volume":"77","author":"K Voelz","year":"2009","unstructured":"Voelz, K., Lammas, D. A. & May, R. C. Cytokine signaling regulates the outcome of intracellular macrophage parasitism by Cryptococcus neoformans. Infect. Immun. 77, 3450\u20133457, https:\/\/doi.org\/10.1128\/IAI.00297-09 (2009).","journal-title":"Infect. Immun."},{"key":"7_CR61","unstructured":"Institute, C.A. L. S. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts 4th edn (CLSI standard M27) (Clinical and Laboratory Standards Institute, 2017)."},{"key":"7_CR62","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.diagmicrobio.2009.02.007","volume":"64","author":"MC Pappalardo","year":"2009","unstructured":"Pappalardo, M. C. et al. Susceptibility of clinical isolates of Cryptococcus neoformans to amphotericin B using time-kill methodology. Diagn. Microbiol. Infect. Dis. 64, 146\u2013151, https:\/\/doi.org\/10.1016\/j.diagmicrobio.2009.02.007 (2009).","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"7_CR63","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.diagmicrobio.2004.08.013","volume":"51","author":"L Nooney","year":"2005","unstructured":"Nooney, L., Matthews, R. C. & Burnie, J. P. Evaluation of Mycograb, amphotericin B, caspofungin, and fluconazole in combination against Cryptococcus neoformans by checkerboard and time-kill methodologies. Diagn. Microbiol. Infect. Dis. 51, 19\u201329, https:\/\/doi.org\/10.1016\/j.diagmicrobio.2004.08.013 (2005).","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"7_CR64","doi-asserted-by":"publisher","first-page":"4314","DOI":"10.1128\/AAC.00904-13","volume":"57","author":"G Del Gaudio","year":"2013","unstructured":"Del Gaudio, G. et al. Antifungal activity of the noncytotoxic human peptide hepcidin 20 against fluconazole-resistant Candida glabrata in human vaginal fluid. Antimicrob. Agents Chemother. 57, 4314\u20134321, https:\/\/doi.org\/10.1128\/AAC.00904-13 (2013).","journal-title":"Antimicrob. Agents Chemother."},{"key":"7_CR65","doi-asserted-by":"publisher","unstructured":"Ganeshkumar, A. et al. Sclareolide as antifungal strategy against Cryptococcus neoformans: unveiling its mechanisms of action. Microorganisms 12, https:\/\/doi.org\/10.3390\/microorganisms12112324 (2024).","DOI":"10.3390\/microorganisms12112324"},{"key":"7_CR66","doi-asserted-by":"publisher","unstructured":"Spadari, C. C., Vila, T., Rozental, S. & Ishida, K. Miltefosine has a postantifungal effect and induces apoptosis in Cryptococcus yeasts. Antimicrob. Agents Chemother. 62, https:\/\/doi.org\/10.1128\/AAC.00312-18 (2018).","DOI":"10.1128\/AAC.00312-18"},{"key":"7_CR67","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.micinf.2011.01.015","volume":"13","author":"F Sangalli-Leite","year":"2011","unstructured":"Sangalli-Leite, F. et al. Amphotericin B mediates killing in Cryptococcus neoformans through the induction of a strong oxidative burst. Microbes Infect. 13, 457\u2013467, https:\/\/doi.org\/10.1016\/j.micinf.2011.01.015 (2011).","journal-title":"Microbes Infect."},{"key":"7_CR68","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.04562-22","volume":"11","author":"Y Liu","year":"2023","unstructured":"Liu, Y. et al. Antifungal peptide SP1 damages polysaccharide capsule of Cryptococcus neoformans and enhances phagocytosis of macrophages. Microbiol. Spectr. 11, e0456222. https:\/\/doi.org\/10.1128\/spectrum.04562-22 (2023).","journal-title":"Microbiol. Spectr."},{"key":"7_CR69","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.3389\/fmicb.2017.02161","volume":"8","author":"P Kumari","year":"2017","unstructured":"Kumari, P. et al. Antifungal and anti-biofilm activity of essential oil active components against Cryptococcus neoformans and Cryptococcus laurentii. Front. Microbiol. 8, 2161, https:\/\/doi.org\/10.3389\/fmicb.2017.02161 (2017).","journal-title":"Front. Microbiol."},{"key":"7_CR70","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.biomaterials.2009.09.087","volume":"31","author":"LR Martinez","year":"2010","unstructured":"Martinez, L. R. et al. The use of chitosan to damage Cryptococcus neoformans biofilms. Biomaterials 31, 669\u2013679, https:\/\/doi.org\/10.1016\/j.biomaterials.2009.09.087 (2010).","journal-title":"Biomaterials"},{"key":"7_CR71","doi-asserted-by":"publisher","DOI":"10.1016\/j.fgb.2019.103258","volume":"132","author":"HH Lee","year":"2019","unstructured":"Lee, H. H., Del Pozzo, J., Salamanca, S. A., Hernandez, H. & Martinez, L. R. Reduced phagocytosis and killing of Cryptococcus neoformans biofilm-derived cells by J774.16 macrophages is associated with fungal capsular production and surface modification. Fungal Genet. Biol. 132, 103258. https:\/\/doi.org\/10.1016\/j.fgb.2019.103258 (2019).","journal-title":"Fungal Genet. Biol."},{"key":"7_CR72","doi-asserted-by":"publisher","first-page":"15675","DOI":"10.1073\/pnas.232568599","volume":"99","author":"E Mylonakis","year":"2002","unstructured":"Mylonakis, E., Ausubel, F. M., Perfect, J. R., Heitman, J. & Calderwood, S. B. Killing of Caenorhabditis elegans by Cryptococcus neoformans as a model of yeast pathogenesis. Proc. Natl. Acad. Sci. USA 99, 15675\u201315680, https:\/\/doi.org\/10.1073\/pnas.232568599 (2002).","journal-title":"Proc. Natl. Acad. Sci. USA"}],"container-title":["npj Fungal Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s44512-026-00007-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44512-026-00007-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44512-026-00007-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T12:57:52Z","timestamp":1792155472000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s44512-026-00007-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,16]]},"references-count":72,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["7"],"URL":"https:\/\/doi.org\/10.1038\/s44512-026-00007-y","relation":{},"ISSN":["3091-3896"],"issn-type":[{"value":"3091-3896","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,16]]},"assertion":[{"value":"24 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"L.R.M. reports a patent (issued and pending) assigned to the University of Florida. All the other authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"6"}}